Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/the-new-england-journal-of-medicine/pneumocystis-pneumonia-associated-with-infliximab-in-japan-PHy4k7lr0L
References (7)
-
N. Miyasaka, T. Takeuchi, K. Eguchi (2005)
Official Japanese guidelines for the use of infliximab for rheumatoid arthritisModern Rheumatology, 15
-
T. Takeuchi, Y. Tatsuki, Y. Nogami, N. Ishiguro, Yoshiya Tanaka, H. Yamanaka, N. Kamatani, M. Harigai, J. Ryu, K. Inoue, H. Kondo, S. Inokuma, T. Ochi, T. Koike (2007)
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 67
-
A. Yasuoka, N. Tachikawa, K. Shimada, S. Kimura, S. Oka (1996)
(1-->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumoniaClinical Diagnostic Laboratory Immunology, 3
-
F. Arnett, S. Edworthy, D. Bloch, D. McShane, J. Fries, N. Cooper, L. Healey, S. Kaplan, M. Liang, H. Luthra, T. Medsger, D. Mitchell, D. Neustadt, R. Pinals, J. Schaller, J. Sharp, R. Wilder, G. Hunder (1988)
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.Arthritis and rheumatism, 31 3
-
F. Pilsczek, A. Karcic, I. Freeman (2003)
Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.Heart & lung : the journal of critical care, 32 2
-
B. Chandrasekaran, A. Kurbaan (2002)
Myocardial Infarction with Angiographically Normal Coronary ArteriesJournal of the Royal Society of Medicine, 95
-
B. Ledergerber, A. Mocroft, P. Reiss, H. Furrer, O. Kirk, M. Bickel, C. Uberti-Foppa, C. Pradier, A. Monforte, Margriet Schneider, J. Lundgren (2001)
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.The New England journal of medicine, 344 3
- Publisher
- The New England Journal of Medicine
- Copyright
- Copyright © 2007 Massachusetts Medical Society. All rights reserved.
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- DOI
- 10.1056/NEJMc070728
- pmid
- 17978303
- Publisher site
- See Article on Publisher Site
Abstract
To the Editor: Infliximab, a monoclonal antibody against tumor necrosis factor α (TNF-α), is used in Japan for the treatment of patients with active rheumatoid arthritis that is resistant to methotrexate.1 Methotrexate is used only for patients who do not have a response to or cannot tolerate other disease-modifying antirheumatic drugs, such as sulfasalazine. Infliximab is not used as primary therapy for rheumatoid arthritis in Japan. Strict postmarketing surveillance of infliximab and etanercept, a drug that blocks the action of TNF, revealed incidences of pneumocystis pneumonia in Japanese patients with rheumatoid arthritis that were higher (0.4% and 0.2%, respectively) than . . .
Journal
The New England Journal of Medicine – The New England Journal of Medicine
Published: Nov 1, 2007